Dr. Lattermann of the Mayo Clinic detailed how medicinal signaling cells interact with a patient's cartilage cells to repair damaged tissue.

This biological process is central to the RECLAIM therapy, a treatment designed to restore joint health by creating an environment conducive to regeneration. Because cartilage has a limited ability to heal itself, the use of signaling cells represents a targeted approach to trigger the body's own repair mechanisms.

According to a video released as part of Season 5, Episode 5 [1], the therapy relies on the combined activity of two different cell types. Dr. Lattermann said that medicinal signaling cells (MSCs) work in tandem with the patient's own cartilage cells.

The interaction between these cells is designed to foster the conditions necessary for tissue repair. By introducing these signaling cells, the therapy aims to stimulate the patient's existing cells to rebuild the cartilage matrix, a structure that is often permanently lost in cases of severe joint degeneration.

Dr. Lattermann said the goal of the RECLAIM process is to move beyond temporary symptom management. Instead of merely treating pain, the therapy focuses on the cellular environment to promote actual tissue regrowth.

The Mayo Clinic presentation emphasizes the synergy between the external signaling cells and the internal cartilage cells. This dual-action approach is intended to optimize the regenerative response within the joint, potentially offering a more durable solution for patients with cartilage loss.

“Medicinal signaling cells work in tandem with the patient's own cartilage cells.”

The RECLAIM therapy represents a shift toward regenerative medicine by focusing on the 'signaling' environment of a joint rather than just the physical replacement of tissue. By utilizing medicinal signaling cells to prompt a patient's own cells to act, the approach attempts to overcome the natural biological resistance of cartilage to self-repair.